Boltwood Capital Management Has $455,000 Holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Boltwood Capital Management lessened its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,975 shares of the biopharmaceutical company’s stock after selling 195 shares during the quarter. Boltwood Capital Management’s holdings in Alexion Pharmaceuticals were worth $455,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ALXN. Norges Bank bought a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth approximately $494,584,000. Magnetar Financial LLC bought a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth approximately $184,465,000. Janus Henderson Group PLC boosted its holdings in shares of Alexion Pharmaceuticals by 74.3% during the fourth quarter. Janus Henderson Group PLC now owns 2,697,186 shares of the biopharmaceutical company’s stock worth $421,404,000 after acquiring an additional 1,149,833 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Alexion Pharmaceuticals by 57.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,804,346 shares of the biopharmaceutical company’s stock worth $438,151,000 after acquiring an additional 1,024,729 shares during the period. Finally, Westchester Capital Management LLC bought a new stake in shares of Alexion Pharmaceuticals in the fourth quarter valued at approximately $123,529,000. Institutional investors own 87.27% of the company’s stock.

Several brokerages recently issued reports on ALXN. Wedbush cut Alexion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $175.00 price target for the company. in a research note on Monday, December 14th. Roth Capital boosted their price target on Alexion Pharmaceuticals from $50.00 to $73.00 in a research note on Tuesday, December 15th. Smith Barney Citigroup cut Alexion Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $175.00 price target for the company. in a research note on Tuesday, December 15th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell reiterated a “neutral” rating and issued a $175.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, December 15th. Finally, Royal Bank of Canada boosted their price target on Alexion Pharmaceuticals from $139.00 to $175.00 and gave the company an “outperform” rating in a research note on Monday, December 14th. Eighteen investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $151.83.

Shares of NASDAQ:ALXN traded up $2.46 during trading on Thursday, hitting $154.81. 11,803 shares of the company were exchanged, compared to its average volume of 2,710,022. The business’s 50 day moving average is $152.91 and its 200-day moving average is $140.23. The company has a market capitalization of $34.03 billion, a P/E ratio of 35.60, a price-to-earnings-growth ratio of 0.75 and a beta of 1.33. The company has a quick ratio of 3.26, a current ratio of 3.81 and a debt-to-equity ratio of 0.22. Alexion Pharmaceuticals, Inc. has a 1-year low of $94.23 and a 1-year high of $162.60.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Wednesday, February 3rd. The biopharmaceutical company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.56 by $0.40. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.51 billion. Alexion Pharmaceuticals had a net margin of 16.32% and a return on equity of 23.16%. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.71 earnings per share. As a group, sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 11.14 earnings per share for the current year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

Recommended Story: Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.